Search research articles
Contact Us
Filters
Showing results (61-70 of 89) with videos related to
Page
of 9
Sort By:
Protein Engineering, Design & Selection : PEDS
|
August 19, 2004
Humanization of the anti-CEA T84.66 antibody based on crystal structure data
Paul J Yazaki, Mark A Sherman, John E Shively, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2000
A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies
Wong JYC, D Z Chu, D M Yamauchi, et al.
Immunotechnology : an International Journal of Immunological Engineering
|
February 1, 1996
Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers
A M Wu, W Chen, A Raubitschek, et al.
Cancer Research
|
January 20, 2007
Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy
Vania Kenanova, Tove Olafsen, Lawrence E Williams, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 5, 2012
Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner
Thomas S C Ng, James R Bading, Ryan Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 21, 2007
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma
Amrita Krishnan, Auayporn Nademanee, Henry C Fung, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 26, 2007
Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody
Tove Olafsen, Zhennan Gu, Mark A Sherman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 10, 2000
Human T lymphocyte genetic modification with naked DNA
M C Jensen, P Clarke, G Tan, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 12, 2010
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation
Scott E James, Philip D Greenberg, Michael C Jensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1991
Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial
D L Longo, E Glatstein, P L Duffey, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 89) with videos related to
Sort By:
Page
of 9
Protein Engineering, Design & Selection : PEDS
|
August 19, 2004
Humanization of the anti-CEA T84.66 antibody based on crystal structure data
Paul J Yazaki, Mark A Sherman, John E Shively, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2000
A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies
Wong JYC, D Z Chu, D M Yamauchi, et al.
Immunotechnology : an International Journal of Immunological Engineering
|
February 1, 1996
Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers
A M Wu, W Chen, A Raubitschek, et al.
Cancer Research
|
January 20, 2007
Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy
Vania Kenanova, Tove Olafsen, Lawrence E Williams, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 5, 2012
Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner
Thomas S C Ng, James R Bading, Ryan Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 21, 2007
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma
Amrita Krishnan, Auayporn Nademanee, Henry C Fung, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 26, 2007
Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody
Tove Olafsen, Zhennan Gu, Mark A Sherman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 10, 2000
Human T lymphocyte genetic modification with naked DNA
M C Jensen, P Clarke, G Tan, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 12, 2010
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation
Scott E James, Philip D Greenberg, Michael C Jensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1991
Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial
D L Longo, E Glatstein, P L Duffey, et al.
Page
of 9